Taldefgrobep
Taldefgrobep Alfa in Adults With Overweight and Obesity
Biohaven Therapeutics · Phase 2 · Active, not recruiting · Enrollment 150
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Taldefgrobep Alpha once weekly | n/r | n/r | n/r | n/r |
| Placebo once weekly | n/r | n/r | n/r | n/r |
| Taldefgrobep Alpha once every 4 weeks | n/r | n/r | n/r | n/r |
| Placebo once every 4 weeks | n/r | n/r | n/r | n/r |
Not shown
- Taldefgrobep Alpha once weekly: endpoint not reported
- Placebo once weekly: endpoint not reported
- Taldefgrobep Alpha once every 4 weeks: endpoint not reported
- Placebo once every 4 weeks: endpoint not reported